Craftport Cannabis Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Craftport Cannabis's earnings have been declining at an average annual rate of -18.4%, while the Pharmaceuticals industry saw earnings growing at 27.3% annually. Revenues have been growing at an average rate of 49.5% per year.
Anahtar bilgiler
-18.4%
Kazanç büyüme oranı
8.8%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 23.1% |
| Gelir büyüme oranı | 49.5% |
| Özkaynak getirisi | n/a |
| Net Marj | -4,454.1% |
| Son Kazanç Güncellemesi | 30 Sep 2022 |
Yakın geçmiş performans güncellemeleri
Gelir ve Gider Dağılımı
Craftport Cannabis nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Sep 22 | 0 | -8 | 3 | 0 |
| 30 Jun 22 | 0 | -8 | 3 | 0 |
| 31 Mar 22 | 1 | -10 | 3 | 0 |
| 31 Dec 21 | 1 | -10 | 3 | 0 |
| 30 Sep 21 | 1 | -13 | 3 | 0 |
| 30 Jun 21 | 1 | -12 | 3 | 0 |
| 31 Mar 21 | 1 | -10 | 3 | 0 |
| 31 Dec 20 | 1 | -10 | 3 | 0 |
| 30 Sep 20 | 1 | -1 | 4 | 0 |
| 30 Jun 20 | 0 | -3 | 4 | 0 |
| 31 Mar 20 | 0 | -3 | 5 | 0 |
| 31 Dec 19 | 0 | -4 | 5 | 0 |
| 30 Sep 19 | 0 | -6 | 6 | 0 |
| 30 Jun 19 | 0 | -6 | 6 | 0 |
| 31 Mar 19 | 0 | -6 | 6 | 0 |
| 31 Dec 18 | 0 | -6 | 6 | 0 |
| 30 Sep 18 | 0 | -8 | 5 | 0 |
| 30 Jun 18 | 0 | -7 | 4 | 0 |
| 31 Mar 18 | 0 | -5 | 3 | 0 |
| 31 Dec 17 | 0 | -4 | 2 | 0 |
| 30 Sep 17 | 0 | -2 | 1 | 0 |
| 30 Jun 17 | 0 | -1 | 1 | 0 |
| 31 Mar 17 | 0 | -1 | 1 | 0 |
| 31 Dec 16 | 0 | -1 | 1 | 0 |
Kaliteli Kazançlar: CFT is currently unprofitable.
Büyüyen Kar Marjı: CFT is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: CFT is unprofitable, and losses have increased over the past 5 years at a rate of 18.4% per year.
Büyüme Hızlandırma: Unable to compare CFT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: CFT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (109.7%).
Özkaynak Getirisi
Yüksek ROE: CFT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.